Seoul Pharma서울제약
018680 · KOSDAQ · ₩018680 · 서울제약
₩1,884▼ ₩15 (0.79%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩52B | ₩54B | ₩52B | ₩50B | ₩40B |
| Cost of sales | ₩21B | ₩21B | ₩21B | ₩18B | ₩15B |
| Gross profit | ₩32B | ₩33B | ₩32B | ₩32B | ₩25B |
| Operating income | −₩1.3B | ₩1.5B | ₩1.2B | ₩1.7B | −₩5.7B |
| Net income | ₩754M | ₩1.7B | ₩3.5B | ₩855M | −₩9.7B |
| Net income to shareholders | ₩754M | ₩1.7B | ₩3.5B | ₩855M | −₩9.7B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩72B | ₩72B | ₩63B | ₩62B | ₩62B |
| Current assets | ₩34B | ₩32B | ₩26B | ₩26B | ₩25B |
| Cash and equivalents | ₩9.9B | ₩7.5B | ₩6.6B | ₩12B | ₩14B |
| Total liabilities | ₩31B | ₩31B | ₩25B | ₩27B | ₩43B |
| Current liabilities | ₩15B | ₩14B | ₩21B | ₩14B | ₩29B |
| Borrowings | ₩10B | ₩10B | ₩10B | ₩14B | ₩28B |
| Total equity | ₩41B | ₩40B | ₩39B | ₩35B | ₩19B |
| Shareholders' equity | ₩41B | ₩40B | ₩39B | ₩35B | ₩19B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩1.9B | −₩3B | ₩5.3B | −₩78M | −₩1.7B |
| Capital spending | ₩861M | ₩2.2B | ₩1.9B | ₩1.2B | ₩1.2B |
| Free cash flow | ₩1B | −₩5.2B | ₩3.4B | −₩1.3B | −₩2.8B |
| Dividends paid | — | — | — | ₩0 | ₩0 |
Consolidated where available. Amounts in won.
Also known as: Seoul Pharma / 서울제약 / 018680 / KRX:018680
Source: KRX statistical information